An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
NCT01458249
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Soft Tissue Sarcoma
Interventions
DRUG:
eribulin mesylate
Sponsor
Eisai Co., Ltd.